Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

Both types are effective at managing cholesterol, but researchers have uncovered some surprising side effects. Weight Gain: ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

These drugs reduce the cholesterol your body makes ... get rid of cholesterol in the body and typically reduce LDL levels by 15-30% PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha ...

an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and Daiichi-Sankyo-partnered antibody drug conjugates (ADCs). Declining Sales of Gardasil in ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

So in these three trials, Patients, everyone received a statin but half the group received a placebo drug Jyoti Sharma continued... and the other half received the PCSK9 inhibitors. And what we ...